CellaVision AB (ST:CEVI) — Market Cap & Net Worth
Market Cap & Net Worth: CellaVision AB (CEVI)
CellaVision AB (ST:CEVI) has a market capitalization of $423.52 Million (Skr3.94 Billion) as of September 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #13208 globally and #214 in its home market, demonstrating a 2.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CellaVision AB's stock price Skr165.00 by its total outstanding shares 23851547 (23.85 Million). Also see how large is CellaVision AB's balance sheet for a full breakdown of the balance sheet.
CellaVision AB Market Cap History: 2015 to 2026
CellaVision AB's market capitalization history from 2015 to 2026. Data shows growth from $164.81 Million to $423.52 Million (12.25% CAGR). Also see CEVI cash flow metrics for how efficiently the company converts equity into cash flow.
CellaVision AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CellaVision AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of CellaVision AB for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.53x
CellaVision AB's market cap is 0.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.64x
CellaVision AB's market cap is 2.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $209.01 Million | $265.04 Million | $59.80 Million | 0.79x | 3.50x |
| 2017 | $352.76 Million | $309.31 Million | $69.72 Million | 1.14x | 5.06x |
| 2018 | $474.47 Million | $364.81 Million | $88.69 Million | 1.30x | 5.35x |
| 2019 | $795.33 Million | $461.77 Million | $99.17 Million | 1.72x | 8.02x |
| 2020 | $764.21 Million | $471.44 Million | $89.48 Million | 1.62x | 8.54x |
| 2021 | $811.13 Million | $565.55 Million | $125.34 Million | 1.43x | 6.47x |
| 2022 | $574.90 Million | $639.34 Million | $118.33 Million | 0.90x | 4.86x |
| 2023 | $538.76 Million | $677.29 Million | $130.31 Million | 0.80x | 4.13x |
| 2024 | $558.28 Million | $723.22 Million | $140.72 Million | 0.77x | 3.97x |
| 2025 | $403.50 Million | $758.97 Million | $153.08 Million | 0.53x | 2.64x |
Competitor Companies of CEVI by Market Capitalization
Companies near CellaVision AB in the global market cap rankings as of September 18, 2026. Review CEVI tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CellaVision AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #126 globally with a market cap of $177.76 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #235 globally with a market cap of $107.45 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Abbott Laboratories | NYSE:ABT | $177.76 Billion | $102.23 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.77 |
| #235 | Stryker Corporation | NYSE:SYK | $107.45 Billion | $280.13 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
CellaVision AB Historical Marketcap From 2015 to 2026
Between 2015 and today, CellaVision AB's market cap moved from $164.81 Million to $ 423.52 Million, with a yearly change of 12.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr423.52 Million | +4.96% |
| 2025 | Skr403.50 Million | -27.72% |
| 2024 | Skr558.28 Million | +3.62% |
| 2023 | Skr538.76 Million | -6.29% |
| 2022 | Skr574.90 Million | -29.12% |
| 2021 | Skr811.13 Million | +6.14% |
| 2020 | Skr764.21 Million | -3.91% |
| 2019 | Skr795.33 Million | +67.63% |
| 2018 | Skr474.47 Million | +34.50% |
| 2017 | Skr352.76 Million | +68.78% |
| 2016 | Skr209.01 Million | +26.82% |
| 2015 | Skr164.81 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of CellaVision AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $423.52 Million USD |
| MoneyControl | $423.52 Million USD |
| MarketWatch | $423.52 Million USD |
| marketcap.company | $423.52 Million USD |
| Reuters | $423.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more